Literature DB >> 12866122

Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD-S31.

Masataka Date1, Isao Sakata, Kazuhide Fukuchi, Kiyoshi Ohura, Yasutaka Azuma, Mitsuko Shinohara, Koichi Matsuzaki, Yoshihisa Namiki, Hiroshi Takahashi.   

Abstract

BACKGROUND AND OBJECTIVES: Photodynamic therapy (PDT) is a novel and promising cancer treatment that employs a combination of photosensitizer and visible light. We examined the effect of PDT using a new photosensitizer, PAD-S31, and the 670-nm diode laser in human oral squamous cell carcinomas (SCC). STUDY DESIGN/
MATERIALS AND METHODS: SAS and HSC-4 cell lines were used in all the experiments. Cell viability was determined by a modified MTT assay. Two methods were used for the determination of apoptosis in human oral SCC cells: TUNEL assay and detection of fragmented mono- and oligo-nucleosomes by ELISA. Xenografts of human oral SCC cells were generated in KSN S1c nude mice.
RESULTS: In vitro PDT using PAD-S31 and the 670-nm diode laser showed cytotoxicity that was a function of laser energy, drug concentration, and time to the SAS and HSC-4 cell lines. On the other hand, PAD-S31 without irradiation had no effect on cell viability. The combinated use of PAD-S31 and the laser irradiation showed excellent anti-tumor activity against tumor xenografts without severe side effects. PDT-mediated cell death occurred predominantly by apoptosis in vitro and in vivo.
CONCLUSIONS: The present study demonstrates that PAD-S31 may serve as a potent photosensitizer for PDT. Furthermore, it is expected that this therapy will be clinically useful for the treatment of patients with oral carcinoma. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866122     DOI: 10.1002/lsm.10188

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  1 in total

1.  Efficacy of krypton laser photodynamic therapy for oral mucosa dysplasia in 9,10-dimethyl-1,2-benzanthracene-treated hamsters.

Authors:  Lingyue Shen; Qing Xu; Pingping Li; Guoyu Zhou
Journal:  Oncol Lett       Date:  2013-08-30       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.